The PPARs: from orphan receptors to drug discovery.

By T. Willson, P. Brown, D. Sternbach, B. R. Henke. Journal of Medicinal Chemistry, 2000

1,706 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/0013d858e41c59e6e9887041451b862f36429627

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Daniele Piomelli
2. Mitchell A. Lazar

In Molecular Biology

1. Ralph DeFronzo
2. S. Kersten
3. Mitchell A. Lazar
4. B. Grygiel-Górniak
5. D. Moller
6. Bart Staels
7. Daniele Piomelli
8. Gerald I. Shulman

In Surgery

1. Mitchell A. Lazar
2. B. Grygiel-Górniak
3. Ralph DeFronzo
4. Bart Staels
5. S. Kersten

Citations in the corpus

• Peroxisome Proliferator-Activated Receptor Alpha Target Genes (2010, background): “[10] T.”
• Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. (2015, background): “Moreover, despite numerous reports of beneficial effects of fibrates in mice, species-specific differences may exist in the response to PPARa agonism [32].”
• The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases (2011, background): “[10,11] PPAR-α ligands can be both synthetic or endogenous FAs and FA-derived compounds are natural ligands for PPAR-α.”
• Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review (2014, background): “The effect of bezafibrate, another compound from this group, is wider because it activates all 3 PPAR subtypes (α, γ and δ) at comparable doses to other fibrates [1,5].”
• Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. (2004, background): “Similar beneficial effects on glucose homeostasis can be expected from nonthiazolidinedione PPAR agonists (283, 284).”
• New drug targets for type 2 diabetes and the metabolic syndrome (2001, background): “PPARγ is the predominant molecular target for insulin-sensitizing thiazolidinedione (TZD) drug”
• Cyclooxygenase‐independent actions of cyclooxygenase inhibitors (2001, background): “Three distinct PPAR isoforms—PPARa, d, and g—have been isolated and characterized (147).”